A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma

NCT07691476 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
48
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Yonsei University